Recent Updates
Recently added Catalysts
RNXT Positive Sentiment

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots

Monday, September 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: RenovoRx is advancing targeted oncology treatments with its FDA-cleared RenovoCath device, which utilizes the TAMP therapy platform for precise drug delivery to tumors. CEO Shaun Bagai discusses recent patents and ongoing clinical trials, highlighting the company's innovative approach to cancer care. The discussion also mentions an upcoming presentation at SSO 2025.
Price reaction · baseline $1.1997 (2025-09-29T13:54:00.000Z) · hit during market hours · clean, no other RNXT news in the window
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • RenovoRx is developing innovative targeted oncology therapies.
  • The RenovoCath device offers a novel approach to drug delivery.
  • The TAMP therapy platform could reduce toxicities of traditional chemotherapy.
  • CEO Shaun Bagai shares promising insights into the company's future.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer

Full Press Release Details

RenovoRx, a clinical-stage life sciences company, is developing targeted oncology therapies and has created RenovoCath, an FDA-cleared novel drug delivery device. Its proprietary TAMP therapy platform enables precise delivery of therapeutics across the arterial wall near the tumor site, directly targeting the tumor while potentially reducing the toxicities linked to systemic IV chemotherapy. In this discussion with PharmaShots, Shaun Bagai, CEO of RenovoRx, shares insights on the company’s recent patents, ongoing clinical trials, and its upcoming presentation at SSO 2025.
Read the full transcript on PharmaShots

Frequently Asked Questions

What is RenovoRx developing?

RenovoRx is developing targeted oncology therapies and the RenovoCath device.

What does the TAMP therapy platform do?

The TAMP platform enables precise delivery of therapeutics near tumor sites.

Who is Shaun Bagai?

Shaun Bagai is the CEO of RenovoRx, discussing the company's innovations.

What is the significance of RenovoCath?

RenovoCath is an FDA-cleared device aimed at improving drug delivery to tumors.

When will RenovoRx present at SSO?

RenovoRx will present at the SSO 2025 conference.

ShareAdd on Google
Tags: RNXT Viatris Investor Conferences Healthcare RenovoRx oncology FDA-cleared drug delivery clinical trials
Last updated: Sep 29, 2025

Biotech snapshot

Cash runway
$9M liquidity · $1M/mo burn
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxelPhase 3
Locally Advanced Pancreatic Cancer →

Catalyst track record

+57%
best trade around RNXT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for RNXT.

See every catalyst's timing & PoA →